Literature DB >> 23377197

NK cells dysfunction in systemic lupus erythematosus: relation to disease activity.

Ana Henriques1, Luís Teixeira, Luís Inês, Tiago Carvalheiro, Ana Gonçalves, António Martinho, Maria Luísa Pais, José António Pereira da Silva, Artur Paiva.   

Abstract

Through their cytotoxic capacities and cytokine production, natural killer (NK) cells modulate autoimmune diseases. However, their role in the pathogenesis of systemic lupus erythematosus (SLE) has not been extensively studied. The aim of this study was to analyse the immunophenotypic and functional characteristics of the two major NK cell subsets in SLE and relate them with disease activity. Peripheral blood samples from 44 patients with active (n = 18) and inactive SLE (n = 26) and 30 controls were analysed by flow cytometry to evaluate NK cell subsets, according to: the differential expression of CXCR3 and CD57; expression of granzyme B and perforin; and production of interferon gamma (IFN-γ) and tumor necrosis alpha (TNF-α), after PMA/ionomycin activation. A clear decrease in absolute and relative numbers of circulating NK cells was found in SLE, particularly in active disease, while the proportions of the major NK cell subsets were unaffected. Active SLE was associated with a reduced CXCR3 expression on both NK cell subsets and a lower frequency of CD56(dim) NK cells expressing CXCR3. Furthermore, granzyme B expression was decreased in both SLE groups, but the percentage of NK cells expressing granzyme B and perforin was higher, particularly in active disease. We found a significant decrease in the percentage of CD56(bright) and CD56(dim) NK cells producing TNF-α and of its expression on CD56(dim) NK cells in active disease, while IFN-γ expression on CD56(bright) NK cells was increased in both SLE groups. Our findings suggest that NK cell subsets exhibit unique phenotypic and functional changes that are particularly evident in active SLE, and they may have the potential to affect the disease outcome.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23377197     DOI: 10.1007/s10067-013-2176-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  38 in total

Review 1.  Systemic lupus erythematosus, complement deficiency, and apoptosis.

Authors:  M C Pickering; M Botto; P R Taylor; P J Lachmann; M J Walport
Journal:  Adv Immunol       Date:  2000       Impact factor: 3.543

Review 2.  Interferons and autoimmune disorders.

Authors:  Olivier Meyer
Journal:  Joint Bone Spine       Date:  2009-09-20       Impact factor: 4.929

3.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

4.  Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease.

Authors:  Baptiste Hervier; Vivien Beziat; Julien Haroche; Alexis Mathian; Pierre Lebon; Pascale Ghillani-Dalbin; Lucile Musset; Patrice Debré; Zahir Amoura; Vincent Vieillard
Journal:  Arthritis Rheum       Date:  2011-06

5.  Nuclear-targeting autoantibodies induced nuclear PARP cleavage accompanied by more pronounced decrease of peripheral white blood cells than Ro/SSA and La/SSB antigen-targeting autoantibodies.

Authors:  Ingrid Böhm
Journal:  J Clin Immunol       Date:  2005-03       Impact factor: 8.317

6.  Comparative studies of human FcRIII-positive and negative natural killer cells.

Authors:  A Nagler; L L Lanier; S Cwirla; J H Phillips
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

7.  Frequency and functional activity of Th17, Tc17 and other T-cell subsets in Systemic Lupus Erythematosus.

Authors:  Ana Henriques; Luís Inês; Maura Couto; Susana Pedreiro; Catarina Santos; Mariana Magalhães; Paulo Santos; Isabel Velada; Anabela Almeida; Tiago Carvalheiro; Paula Laranjeira; José Mário Morgado; Maria Luísa Pais; José António Pereira da Silva; Artur Paiva
Journal:  Cell Immunol       Date:  2010-05-11       Impact factor: 4.868

Review 8.  Impaired clearance of dying cells in systemic lupus erythematosus.

Authors:  Udo S Gaipl; Reinhard E Voll; Ahmed Sheriff; Sandra Franz; Joachim R Kalden; Martin Herrmann
Journal:  Autoimmun Rev       Date:  2004-12-08       Impact factor: 9.754

9.  Natural cell mediated cytotoxicity in systemic lupus erythematosus: suppression by antilymphocyte antibody.

Authors:  M Goto; K Tanimoto; Y Horiuchi
Journal:  Arthritis Rheum       Date:  1980-11

10.  Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus.

Authors:  M Herrmann; R E Voll; O M Zoller; M Hagenhofer; B B Ponner; J R Kalden
Journal:  Arthritis Rheum       Date:  1998-07
View more
  25 in total

1.  Alterations on peripheral blood B cell subsets induced by allergic rhinitis.

Authors:  Ana Henriques; Rodrigo Nunes; Graça Loureiro; António Martinho; Maria Pais; António Segorbe-Luís; Hélder Trindade; Celso Pereira; Artur Paiva
Journal:  Inflamm Res       Date:  2015-02-21       Impact factor: 4.575

Review 2.  Could Lymphocyte Profiling be Useful to Diagnose Systemic Autoimmune Diseases?

Authors:  Guillermo Carvajal Alegria; Pierre Gazeau; Sophie Hillion; Claire I Daïen; Divi Y K Cornec
Journal:  Clin Rev Allergy Immunol       Date:  2017-10       Impact factor: 8.667

Review 3.  Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.

Authors:  Nasim Bolouri; Maryam Akhtari; Elham Farhadi; Reza Mansouri; Seyedeh Tahereh Faezi; Ahmadreza Jamshidi; Mahdi Mahmoudi
Journal:  Inflamm Res       Date:  2022-03-17       Impact factor: 4.575

4.  IFN-gamma AU-rich element removal promotes chronic IFN-gamma expression and autoimmunity in mice.

Authors:  Deborah L Hodge; Cyril Berthet; Vincenzo Coppola; Wolfgang Kastenmüller; Matthew D Buschman; Paul M Schaughency; Hidekazu Shirota; Anthony J Scarzello; Jeff J Subleski; Miriam R Anver; John R Ortaldo; Fanching Lin; Della A Reynolds; Michael E Sanford; Philipp Kaldis; Lino Tessarollo; Dennis M Klinman; Howard A Young
Journal:  J Autoimmun       Date:  2014-02-28       Impact factor: 7.094

5.  Analysis of the CD161-expressing cell quantities and CD161 expression levels in peripheral blood natural killer and T cells of systemic lupus erythematosus patients.

Authors:  Yi-Lung Lin; Shih-Chang Lin
Journal:  Clin Exp Med       Date:  2015-11-21       Impact factor: 3.984

6.  Cardif (MAVS) Regulates the Maturation of NK Cells.

Authors:  LaTeira D Haynes; Shilpi Verma; Bryan McDonald; Runpei Wu; Robert Tacke; Heba N Nowyhed; Jennifer Ekstein; Ariana Feuvrier; Chris A Benedict; Catherine C Hedrick
Journal:  J Immunol       Date:  2015-07-31       Impact factor: 5.422

7.  Downregulation of CD3ζ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype.

Authors:  Abel Suárez-Fueyo; Sean J Bradley; Takayuki Katsuyama; Sarah Solomon; Eri Katsuyama; Vasileios C Kyttaris; Vaishali R Moulton; George C Tsokos
Journal:  J Immunol       Date:  2018-03-30       Impact factor: 5.422

8.  Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus.

Authors:  D de J Cruz-González; D Gómez-Martin; E Layseca-Espinosa; L Baranda; C Abud-Mendoza; J Alcocer-Varela; R González-Amaro; A E Monsiváis-Urenda
Journal:  Clin Exp Immunol       Date:  2017-11-22       Impact factor: 4.330

9.  Activation status of CD56dim natural killer cells is associated with disease activity of patients with systemic lupus erythematosus.

Authors:  Manman Liu; Junli Liu; Xiaoyan Zhang; Yichuan Xiao; Gengru Jiang; Xinfang Huang
Journal:  Clin Rheumatol       Date:  2020-08-14       Impact factor: 2.980

10.  Novel Long Non-coding RNA Expression Profile of Peripheral Blood Mononuclear Cells Reveals Potential Biomarkers and Regulatory Mechanisms in Systemic Lupus Erythematosus.

Authors:  Qi Cheng; Mo Chen; Xin Chen; Xiaochan Chen; Huawei Jiang; Huaxiang Wu; Yan Du
Journal:  Front Cell Dev Biol       Date:  2021-06-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.